Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
hospital settings
high-risk individuals intravenous injection immunocompromised patients smallpox outbreaks |
| gptkbp:approves |
gptkb:1980s
|
| gptkbp:available_on |
lyophilized powder
|
| gptkbp:can_be_combined_with |
vaccinia vaccine
|
| gptkbp:can_cause |
serum sickness
|
| gptkbp:clinical_trial |
conducted for efficacy and safety
|
| gptkbp:contains |
antibodies against vaccinia virus
|
| gptkbp:contraindication |
individuals with hypersensitivity to immunoglobulins
|
| gptkbp:developed_by |
gptkb:Centers_for_Disease_Control_and_Prevention
vaccinated human donors |
| gptkbp:dosage_form |
depends on exposure severity
|
| https://www.w3.org/2000/01/rdf-schema#label |
vaccinia immune globulin
|
| gptkbp:indication |
severe eczema or atopic dermatitis patients
|
| gptkbp:is |
a first-line treatment
a vaccine a cure for vaccinia virus infection a substitute for vaccination a treatment for smallpox itself |
| gptkbp:is_associated_with |
improved outcomes in at-risk populations
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_considered |
a critical resource in public health emergencies
a passive immunization therapy a specialized treatment option. an essential medicine by WHO |
| gptkbp:is_effective_against |
other viral infections
|
| gptkbp:is_evaluated_by |
gptkb:guidelines
efficacy in clinical studies safety in pregnant women |
| gptkbp:is_part_of |
gptkb:nuclear_weapons
emergency preparedness plans smallpox vaccination program post-exposure management protocols |
| gptkbp:is_recommended_by |
gptkb:CDC
|
| gptkbp:is_subject_to |
regulatory approval
|
| gptkbp:is_used_by |
gptkb:healthcare_professionals
|
| gptkbp:is_used_for |
prevention of vaccinia virus complications
|
| gptkbp:is_used_in |
certain dermatological conditions
research studies on immunology |
| gptkbp:is_used_to |
reduce severity of adverse reactions
|
| gptkbp:marketed_as |
VIG
|
| gptkbp:produced_by |
plasma of donors vaccinated with vaccinia
|
| gptkbp:requires |
reconstitution before use
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
headache
nausea fever rash chills |
| gptkbp:stored_at |
2 to 8 degrees Celsius
|
| gptkbp:suitable_for |
routine use in healthy individuals
|
| gptkbp:used_for |
treatment of complications from smallpox vaccination
|
| gptkbp:used_in |
post-exposure prophylaxis
|